PDCD1 and lung cancer: Althammer et al [8] conducted a study on image analysis to predict the response to durvalumab therapy targeting the programmed cell death-1/programmed cell death ligand-1 (PD1/PD-L1) pathway in patients with non–small cell lung cancer.